Session Descriptions

Session descriptions will be posted as they become available. Please visit this page regularly for updated information.  
 
Click on the links below to be directed to specific days: 

Saturday, May 5

Opening Plenary (09:00-09:45)

Health Literacy - How Pharmacy Can Help Navigate Health Information for Patients

Tamara Harth, Sunnybrook Health Sciences Centre, Toronto, ON

This presentation will provide an overview of the health literacy principles and how pharmacists can integrate these best practices into their teaching to provide more effective education to patients and families.  This session will enable participants to define health literacy, list the main factors that influence health literacy, understand the universal precautions for health literacy and apply these precautions into their own practices.
 
Learning Objectives:
  1. Define health literacy; 
  2. Understand and describe the personal and system factors that influence health literacy; and
  3. Apply universal precautions for health literacy within pharmacy teaching and practice.

Plenary (09:45-10:30)

Shared Decision Making: Speaking to Patients About Numbers

Derek Jorgenson, University of Saskatchewan, Saskatoon, SK

Poor medication adherence leads to significant morbidity and mortality, in addition to contributing to avoidable health system costs and ballooning drug budgets. The reasons behind this adherence issue are complex and multi-factorial, however, pharmacists may be inadvertently contributing to the problem when speaking to patients about the numbers related to medication benefits and risks. Several studies have found that the words that health providers use when talking to patients about numbers and risk often lead to misinterpretations of the intended message. 
 
The speaker will share information regarding recent studies that highlight best practices in talking to patients about the numbers related to medication benefits and risks. The speaker will also share some useful tools and technologies to assist in applying these best practices in real-world practice. This presentation will assist pharmacists to more effectively talk to patients about numbers to ensure that patients understand the actual risks and benefits of their medications to facilitate shared and informed decisions regarding drug therapies. 
 
Learning Objectives:
  1. Discuss the problem of poor medication adherence with chronic medications;
  2. Describe how pharmacists may be inadvertently contributing to poor medication adherence when speaking to patients about the numbers related to medication benefits and risks;
  3. Discuss recent studies that highlight best practices in talking to patients about the numbers related to medication benefits and risks; and
  4. Assist pharmacists to more effectively talk to patients about numbers to ensure that patients understand the actual risks and benefits of their medications to facilitate shared and informed decisions regarding drug therapies that patients.

Back to top

CAPhO Awards (11:10-11:40)

Presentation of Volunteer Recognition Award, Student Member Award, Preceptor / Mentorship Award and CAPhO Merit Award. 

Plenary (11:40-12:25)

Medical Cannabis and the Oncology Patient: What Every Health Care Practitioner Needs to Know 

Danial Schecter, Cannabinoid Medical Clinic, Toronto, ON
 
There is an increasing amount of interest in the use of medical cannabis for a variety of different symptoms and conditions. Health care providers (HCPs) are being asked on a daily basis if cannabis is right for them, what is the current state of evidence, what are the regulations surrounding its use and how to use it safely and efficiently. Unfortunately, there is little education provided in professional school about medical cannabis and its underlying mechanism of action. This session will provide pharmacists with the required knowledge to answer the most commonly encountered questions.
 
Learning Objectives:
  • Conceptualize the endocannabinoid system and function
  • Describe cannabinoid availability in Canada and regulations surrounding access to cannabis for medical purposes
  • Explain the role of cannabis in oncology patients for symptom management including chemotherapy induced nausea and vomiting, pain, anxiety and sleep
  • Discuss the pre-clinical evidence of cannabis as an anti-cancer agent
 

CAPhO Annual General Meeting (12:25-13:00)

All Conference participants are welcome to attend. CAPhO members are encouraged to attend the AGM and have a chance to win a free registration to the CAPhO Conference 2019. Tickets will be distributed at the entrance to the AGM. You have to be present to win!

Panel (14:00-14:40)

Post Cancer Treatment – The New Normal

Hélène Bourget-Letarte, The Ottawa Hospital, Ottawa, ON
Frances Cusano, Tom Baker Cancer Centre, Calgary, AB
Alex Hajjar, University of Ottawa, Ottawa, ON
 
Being told you have cancer will change you forever, especially if you have worked in oncology. It may be difficult to hear anything else that is said after the word “cancer.” This session will provide pharmacy professionals with wisdom into the patient experience through their stories about the impact of chemotherapy. 
 
Learning Objectives:
  1. Acquire an appreciation of the magnitude of what going through chemotherapy means through real world stories,
  2. Identify ways in which this knowledge can enhance how we discuss chemotherapy with our patients; and
  3. Go forward with an understanding that once treatment is complete, getting back to life as it was before cancer is not the goal but rather to empower “life after chemo” as the new normal. 

Back to top

Concurrent Sessions 1 (14:45-15:25)

Practical Simulation-Based Education and Training for Oncology Pharmacy Professionals

Jason Wentzell, The Ottawa Hospital, Ottawa, ON
 
Target audience: Pharmacy educators, clinical pharmacists, pharmacy researchers, pharmacy administrators
 
Simulation Education Training (SET) in healthcare settings provides an excellent opportunity for health professionals to learn, practice and reflect upon the performance of new or existing technical or clinical skills in a safe, observed and constructive environment.  Medical SET has been demonstrated to enhance a participant’s clinical competence, improve patient safety, promote collaboration and reduce health care costs. SET can be employed over a spectrum of pharmacy professional roles, from pharmacy learners to experienced practitioners as a method to introduce new, or improve existing skillsets, procedures or practices.
 
The formal SET scenario design process involves six core steps, the result of which yield a focused simulation, intended to address specific practice objectives.  Once the scenario is developed, intended candidates participate in formal pre-briefing, simulation scenario and debriefing sessions.  Structured, facilitated debriefing and feedback sessions helps participants to reflect, close knowledge gaps and improve the desired skillset.  
 
SET is a practical and potentially invaluable method to provide oncology pharmacy professionals with an opportunity to practice and/or develop new skills, train learners and staff, address identified performance gaps or inadequacies, improve practice efficiency and standardization and ultimately enhance patient care.  
 
Learning Objectives:
  1. Be able to explain why oncology practice is such an optimal area to incorporate simulation-based education and training for healthcare professionals;
  2. Be able to state and explain the six steps of simulation scenario design; 
  3. Be able to state and explain the three principle components of a simulation education training (pre-briefing, conducting the simulation scenario and debriefing & feedback); and
  4. Acquire a basic comprehension of how to incorporate simulation-based education and training into practice through review of an example simulation scenario. 

Human Error and Oral Chemotherapy: An Exploratory Study in Nova Scotia

Rachel Gilbert, Rachel Gilbert Consulting, Toronto, ON
 
Target audience: Pharmacy technicians, pharmacy assistants, pharmacy administrators, pharmacy educators, pharmacy researchers, clinical pharmacists
 
“We cannot change the human condition, but we can change the conditions under which humans work.”
-James Reason
 
Oral chemotherapy is increasingly being prescribed as anti-cancer therapy. In contrast to IV chemotherapy, which is delivered in hospital, oral chemotherapy is usually delivered in the community and home, where there is less control and more variability. This presentation will summarize the results of an exploratory observational study in Nova Scotia, which aimed to identify potential human errors relating to oral chemotherapy.
 
*Note: This study was funded by a grant from Cancer Care Nova Scotia under the guidance of the late Larry Broadfield. Melissa Kozak and Rachel Gilbert conducted the data collection and analysis while members of the HumanEra team at University Health Network. 
 
Learning Objectives:
  1. Understand the relationship between the different areas of the oral chemotherapy system as they relate to error;
  2. Describe at least 3 potential mechanisms of human error with oral chemotherapy; and 
  3. List at least 3 approaches to error prevention in oral chemotherapy.

Tumour Lysis Syndrome in the Context of Emerging Anti-cancer Therapies

Melanie Trinacty, The Ottawa Hospital, Ottawa, ON
 
Target audience: Clinical pharmacists, pharmacy educators
 
Tumour lysis syndrome(TLS) is an oncologic emergency that may occur either spontaneously or after initiation of cytotoxic therapy in patients with cancer.  There are potentially severe complications associated with TLS and the pharmacist can play a significant role in identifying high-risk patients and implementing preventative therapies or treatments in the event that TLS does occur.  This session will review the clinical and laboratory definitions of TLS, emphasize the pharmacist’s role in TLS education and management, and review new protocols implemented in this new era of small molecules and targeted therapies. 
 
Learning Objectives:
  1. Identify patients who may be at risk for treatment-related tumor lysis syndrome (TLS);
  2. Discuss risk of developing TLS with patients and family members;
  3. Describe the clinical manifestations and laboratory values which may indicate TLS; and
  4. Tailor therapies for TLS based on individual patient characteristics (including fixed-dose rasburicase). 

Opioid Crisis - How is the Oncology Patient Affected?

Kelly Grindrod, University of Waterloo, Waterloo, ON
 
Target audience: Clinical pharmacists, pharmacy educators
 
The opioid crisis is forcing the entire healthcare system to pay closer attention to opioid prescribing. Whether we are treating surgical pain, chronic pain, or cancer pain, opioid use is controversial. As a profession, pharmacists need to develop strategies to get ahead of this crisis while still supporting our patients in achieving good pain control. This session will examine what we know about the broader opioid crisis and use a case-based approach to consider how this may impact pain management in oncology.
 
Learning Objectives:
  1. To review changing role of opioids in pain management;
  2. To discuss how patients can be educated about safe opioid use;
  3. To describe what we know about opioid use and how it relates to opioids in the community; and
  4. To use a case-based approach to exploring the role of opioids in cancer pain management.
 

Concurrent Sessions 2 (16:05-16:45)

Chemotherapy-induced Peripheral Neuropathy

Chris Ralph, Tom Baker Cancer Centre, Calgary, AB
 
Target audience: Clinical pharmacists, pharmacy educators
 
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting neurotoxic effect affecting many patients receiving chemotherapy, characterized by pain and loss of sensation in the hands and feet. It can interfere with cancer patients’ treatment and significantly reduce their quality of life. With better treatment options like new anti-emetics and hematopoietic colony stimulating factors for other serious side-effects, CIPN emerges more often as a dose limiting factor. In this session, we will discuss prevention, monitoring, pharmaceutical treatment options, as well as other modalities to consider. We will also explore future management options for this pervasive, debilitating adverse effect of cancer treatment.
 
Learning Objectives:
  1. Describe the sign and symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN) highlighting the offending neurotoxic agents;
  2. Construct a CIPN management strategy incorporating best practices; and
  3. Apply pharmaceutical treatment options along with other modalities to consider.

How to Make Pharmacy Recommendations so Others Will Listen

Nathan Lockhart, Spectrum Solutions, Ottawa, ON
 
Target audience: Pharmacy technicians, pharmacy assistants, clinical pharmacists, pharmacy educators
 
Opportunities to present information are everywhere in our professional and personal lives, but for many of us, having to speak is a significant challenge and a source of anxiety. Health care professionals are increasingly time constrained and pushed and pulled in different directions because of multiple issues competing for their attention. As a result, we may only have a few minutes in which to communicate a recommendation. Of course, the people on the receiving end of the recommendation may also have limited, time, energy and desire to listen. 
 
Learning Objectives:
  1. Structure an efficient recommendation; 
  2. Maximize verbal and non-verbal communication; and 
  3. Avoid the most common problems when speaking.  

Chemotherapy-induced Nausea and Vomiting (CINV) Control in Adults and Children: Mind the Gap!

Lee Dupuis, The Hospital for Sick Children, Toronto, ON
 
Target audience: Clinical pharmacists, pharmacy educators
 
Chemotherapy-induced vomiting (CIV) prophylaxis is highly effective in adult patients. So much so that CIV has now been described as a negligible problem.  Conversely, CIV control remains poor in children even when guideline-consistent prophylaxis is given.  Understanding the extent of and the possible explanations for this gap will assist pediatric clinicians to improve chemotherapy-induced nausea control in their patients and will frame the research agenda in this field.
 
Learning Objectives: 
  • Describe guideline-consistent CIV prophylaxis for pediatric patients;
  • Compare CIV control rates in adult and pediatric patients; and
  • Identify possible explanations for the relatively low CIV control rate seen in pediatric patients. 

Potential Strategies to Extend Beyond-Use-Date: The Ontario Experience

Ron Fung, Cancer Care Ontario, Toronto, ON
 
Target audience: Pharmacy administrators, pharmacy educators, pharmacy technicians, pharmacy assistants, pharmacy researchers
 
According to the National Association of Pharmacy Regulatory Authorities (NAPRA) Model Standards, the Beyond-Use-Date (BUD) for single-dose vials is 6 hours.  Assigning a BUD based on 6 hour sterility standards may have significant financial implications to systemic treatment facilities in Ontario.  To address the drug waste issue related to implementation of the NAPRA Model Standards, a BUD Mitigation Strategy Working Group was created and led by the Systemic Treatment Program at Cancer Care Ontario.  The primary objective of the Working Group was to develop a Recommendations Report which complies with the NAPRA Model Standards for BUD and provides potential mitigation strategies to minimize wastage due to single-dose vials.  The Recommendations Report focuses on four key areas with potential for the greatest system impact: closed-system drug-transfer devices, dose rounding, facility-level sterility testing, and automated robotic dispensing units. 
 
Learning Objectives: 
  1. Describe the NAPRA Model Standards for the Pharmacy Compounding of Hazardous and Non-Hazardous Sterile Preparations;
  2. Understand the potential financial impact of BUD in a publicly funded cancer system; and
  3. Review the key components of Cancer Care Ontario’s Beyond-Use-Date Recommendations Report.

Back to top

Sunday, May 6

CAPhO Town Hall Breakfast Meeting (08:30-09:15)

Influence and contribute to the growth and development of your association by discussing what matters the most with the CAPhO Executive Committee and fellow members. A light breakfast will be offered during this session.

CAPhO Poster Award Presentations (09:15-09:45)

CAPhO Poster Awards will be presented for the best posters in Research (Clinical), Research (Non-clinical), Pharmacy Practice and Administration. Award recipients will make a short presentation summarizing the subject of their poster.

Hot Topic Cluster Discussions (09:45-10:30)

During the Hot Topic Discussions, participants will have the opportunity to discuss two of the nine available topics, each led by a different facilitator. Read below for details on the topics and facilitators for this session. Participation is limited and sign up is required during online registration.

1. Beyond the Hood: Pharmacy Technicians and Clinical Trials

Kathy LeBreux, The Ottawa Hospital, Ottawa, ON

Kathy will share her interesting role as a Registered Pharmacy Technician working in the challenging world of Oncology Clinical Trials. From the Site initiation Visit to the final close-out visit and everything in between.  Phase 1, 1st in Human and exciting Oncolytic Virus trials will also be discussed.

2. Fertility Preservation and Chemotherapy

Melanie Trinacty, The Ottawa Hospital, Ottawa,ON

Fertility preservation is a quality of life issue that is now impacting cancer survivors. This session will be a discussion focusing on: what options are available to patients, the timeframe required for each option and the resources available to health care professionals and patients.

3. How to Clean the Clean Room 

Samantha Wright, The Ottawa Hospital, Ottawa, ON

This session will cover the process on how to implement a new cleaning and disinfection procedure in areas reserved for hazardous sterile preparations. It will also cover the main stakeholders in who should be involved in the cleaning procedure implementation (i.e. infection control, environmental services, pharmacy).
 
The session will also cover the development of a comprehensive training procedure for cleaning and disinfecting personnel, as well as the creation of a safe work practice document outlining PPE, product/equipment and storage, maintenance logs and cleaning frequency.

4. Magical, Mysterious, Mischievous: Methadone in Cancer Pain Management

Chris Ralph, Tom Baker Cancer Centre, Calgary, AB

With a complex pharmacological profile, methadone can be an intimidating medication when considering options in the management of cancer pain. It does have several beneficial and unique characteristics distinguishing it from other opioids. In this informal discussion, we will explore clinical scenarios when methadone would be an option, with a focus on the outpatient setting.

5. Monitoring Patients on Checkpoint Inhibitors: What to Expect and When 

Glenn Myers, Horizon Health Network, Moncton, NB

Immune checkpoint inhibitors (ICIs) open a new world of pharmacotherapy for treatment of immune-sensitive malignancies. The exciting prospect of ICIs also comes with new risks for potentially life threatening immune related adverse events (irAEs) that require unique assessment and monitoring compared to conventional chemotherapy or anti-cancer targeted therapy. This interactive session will serve as a primer to equip the clinical pharmacist with the biochemical and clinical monitoring strategies required to proactively identify and manage irAEs in patients receiving ICIs.

6. Helping Older Adults Find Useful Health Information Online 

Kelly Grindrod, University of Waterloo, Waterloo, ON

This session will review some practical tips for helping patients find useful information online, especially individuals who are older and those who have low health literacy.

7. Oncology Drug Shortages: How Are We Coping? 

Ivan Tyono, Sunnybrook Health Sciences Centre, Toronto, ON

An opportunity to discuss, share and learn from one another on strategies to manage drug shortages pre-emptively and reactively during these difficult times.  A forum to vent some of your frustrations to those who understand what you’re going through.

8. Oral GVHD Management 

Tiffany Nguyen, The Ottawa Hospital, Ottawa, ON

Oral GVHD is a common complication of hematopoietic stem cell transplantation. Choosing an appropriate topical application can be a challenge. Bring your steroid suspension recipes with you to our discussion group! Let’s review management options together.

9. Pharmacist Prescribing Collaborative Care 

Esther Jadusingh, Alberta Children's Hospital, Calgary, AB

An informal discussion on pharmacist prescribing practices in the inpatient and ambulatory settings in pediatric Hematology, Oncology and Stem Cell Transplant.

Plenary (10:45-11:30)

Management of Cancer-associated Thrombosis

Marc Carrier, The Ottawa Hospital, Ottawa, ON

Learning Objectives:
  1. To review the evidence for the acute and long-term treatment of Cancer-Associated Thrombosis (CAT);
  2. To discuss the use of the Direct Oral Anticoagulants for the management of CAT; and
  3. Review predictors of recurrent venous thrombosis and major bleeding in patients with CAT.

Plenary (11:30-12:15)

“Building and Maintaining Resiliency”: a Wellness Session for Healthcare Providers working in Oncology 

Caroline Gérin-Lajoie, University of Ottawa, Ottawa, ON
 
The health care environment is becoming increasingly stressful to work in, as we face challenges such as increased patient volumes, increased focus on the patient experience, changes in models of care, increased chronicity and complexity of medical illness, ethical issues, technostress and economic cuts. In addition, healthcare professionals working in oncology must deal with highly emotional circumstances, such as limitations in treatment, serious and terminal illness, as well as loss of patients. The impact of these issues on clinicians’ health can be significant and themes of burnout and resiliency have been gaining interest.
 
This empowering session on “Building and Maintaining Resiliency” will acknowledge the challenges of working in healthcare, with a specific emphasis on the field of oncology. The concepts of burnout and resiliency will be discussed and approaches to building and maintaining resiliency will be presented. 
 
Learning Objectives
  1. To acknowledge the personal challenges related to working in oncology;
  2. To highlight risk factors and recognize the symptoms associated with burnout; 
  3. To introduce the concept of resiliency; and
  4. To summarize recent models and skills to build and maintain resiliency.